Abstract 60P
Background
The studies on hypo-fractionation for GBM showed 5-12 months median overall survivals not inferior to standard fractionation protocols. We aimed to describe the feasibility of extreme hypo fractionation combined with temozolamide for newly diagnosed and recurrent GBM.
Methods
During Dec 2015- Dec 2017, 60 patients of biopsy proven GBM were retrospectively scrutinized and were analysed. PTV was defined on FLAIR/T2 signal coverage with 4 mm margin and GTV was defined as contrast enhanced tumor. PTV was prescribed with 5 Gy (range: 4.5-6 Gy) in five fractions at isocenter and GTV was prescribed as single fraction SRS as 8 Gy (range: 6-12 Gy) at 75% (range: 65-90%) isodose line. Radiation was completed in 8 days. Temozolamide was given as 100mg daily for 8 days.
Results
Mean age was 45 years (range: 22- 74 years). 40(66.66%) patients were male and 20(33.33%) were female. CR was found in 07 (11.66%) patients, PR was seen in 28 (46.66%) patients. SD was observed in 20 (33.33%) patients. 05 (8.33%) had PD during first 3-4 months. Treatment was tolerated very well. Only 5 patients used corticosteroids for 3 months. Median follow-up time was 24 months (range: 08-32 months). Median survival in newly diagnosed patients was 12.5 months (range: 4.5 -16 months), while in recurrent cases it was 8.5 months (range: 3 -11 months).
Conclusions
Extreme hypo-fractionation combined with temozolamide is safe and an effective approach to manage GBM cases and survivals are also comparable to the standard approaches. Further randomized studies are warranted to establish its regular use.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
88P - The Sidra LUMC advanced colon cancer NGS cohort
Presenter: Wouter Hendrickx
Session: Poster display session
Resources:
Abstract
89P - A phase II trial of adjuvant chemoradiotherapy for patients with high-risk rectal submucosal invasive cancer after local resection
Presenter: Masaaki Noguchi
Session: Poster display session
Resources:
Abstract
90P - High MICB expression confers prognostic benefit in colorectal cancer
Presenter: Shanchao Yu
Session: Poster display session
Resources:
Abstract
91P - Adjuvant therapy for high-risk stage II or stage III colon adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study
Presenter: Chien-Hsin Chen
Session: Poster display session
Resources:
Abstract
92P - Prospective randomized controlled study comparing primary surgery versus neoadjuvant chemotherapy followed by surgery in gastric carcinoma
Presenter: Vipin Goel
Session: Poster display session
Resources:
Abstract
93P - Biomarker selection of liver metastatic colorectal patients for anti-EGFR monoclonal antibodies: A machine learning analysis
Presenter: Yijiao Chen
Session: Poster display session
Resources:
Abstract
94P - NORTH/HGCSG1003: North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: Final analysis
Presenter: Michio Nakamura
Session: Poster display session
Resources:
Abstract
95P - Anatomical resections improve relapse-free survival in patients with KRAS/NRAS/BRAF- mutated colorectal liver metastases
Presenter: Ye Wei
Session: Poster display session
Resources:
Abstract
96P - Incidence, characteristics and prognosis in colorectal cancer with CNS metastases
Presenter: Nicola Taylor
Session: Poster display session
Resources:
Abstract
97P - The role of adjuvant chemotherapy according to the status of surgical margin in rectal cancer
Presenter: Jong Hoon Lee
Session: Poster display session
Resources:
Abstract